GCL
RVNC

Glazer Capital LLC’s Revance Therapeutics, Inc. RVNC Stock Holding History

Glazer Capital LLC’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,210
Closed -$249K – 161
2024
Q3 		$249K Buy
+3,210
New +$16K 0.01% 106

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glazer Capital LLC's RVNC Position: Q1 2025 in Review

Glazer Capital LLC sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,950,000 shares — an estimated $5.93M sold.

Glazer Capital LLC first reported a position in RVNC in Q4 2024 and held it in 1 quarter. The position peaked at $5.93M in Q4 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Glazer Capital LLC reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Glazer Capital LLC sold 1,950,000 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $5.93M.
  • Glazer Capital LLC first reported a position in Revance Therapeutics, Inc. in Q4 2024 and held it in 1 quarter.
  • Glazer Capital LLC's Revance Therapeutics, Inc. position peaked at $5.93M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Glazer Capital LLC's 13F filing for Q1 2025, filed 15 May 2025.